UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Alzheimer's & dementia, 2017-10, Vol.13 (10), p.1117-1124

2017

Volltextzugriff (PDF)

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2010-01, Vol.35 (2), p.581-590

2010

Volltextzugriff (PDF)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

BMC psychiatry, 2011-12, Vol.11 (1), p.203-203, Article 203

2011

Volltextzugriff (PDF)

DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1260-P1260

2017

Volltextzugriff (PDF)

The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly

Neurologic clinics, 2017-05, Vol.35 (2), p.231-262

2017

Volltextzugriff (PDF)

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

BMC psychiatry, 2009-07, Vol.9 (1), p.44-44, Article 44

2009

Volltextzugriff (PDF)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

BMC psychiatry, 2011-02, Vol.11 (1), p.23-23, Article 23

2011

Volltextzugriff (PDF)

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

Journal of clinical psychopharmacology, 2011-06, Vol.31 (3), p.349-355

2011

Volltextzugriff (PDF)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

BMC psychiatry, 2010-11, Vol.10 (1), p.89-89, Article 89

2010

Volltextzugriff (PDF)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Therapeutics and clinical risk management, 2008-08, Vol.4 (4), p.713-720

2008

Volltextzugriff (PDF)

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

Journal of clinical psychopharmacology, 2005-06, Vol.25 (3), p.255-258

2005

Volltextzugriff (PDF)

Mating-Induced c-fos Expression Patterns Complement and Supplement Observations after Lesions in the Male Syrian Hamster Brain

Annals of the New York Academy of Sciences, 1997-01, Vol.807 (1), p.239-259

1997

Volltextzugriff (PDF)

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

BMC psychiatry, 2013-05, Vol.13 (1), p.143-143, Article 143

2013

Volltextzugriff (PDF)

Expression of c-fos gene activation during rough and tumble play in juvenile rats

Brain research bulletin, 2002-03, Vol.57 (5), p.651-659

2002

Volltextzugriff (PDF)

Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials

Journal of clinical psychopharmacology, 2010-06, Vol.30 (3), p.286-289

2010

Volltextzugriff (PDF)

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

Psychiatry research, 2011-05, Vol.187 (1), p.42-48

2011

Volltextzugriff (PDF)

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

Schizophrenia research, 2008-07, Vol.102 (1), p.230-240

2008

Volltextzugriff (PDF)

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia

The international journal of neuropsychopharmacology, 2003-06, Vol.6 (2), p.97-102, Article S1461145703003389

2003

Volltextzugriff (PDF)

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics

The journal of clinical psychiatry, 2001, Vol.62 Suppl 2, p.35

2001

Volltextzugriff (PDF)

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

Schizophrenia research, 2011-08, Vol.130 (1), p.11-19

2011

Volltextzugriff (PDF)

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

Progress in neuro-psychopharmacology & biological psychiatry, 2004-09, Vol.28 (6), p.985-996

2004

Volltextzugriff (PDF)

Mating‐Induced c‐fos Expression Patterns Complement and Supplement Observations after Lesions in the Male Syrian Hamster Braina

Annals of the New York Academy of Sciences, 1997-01, Vol.807 (1), p.239-259

1997

Volltextzugriff (PDF)

Incidence of Tardive Dyskinesia in Older Adult Patients Treated With Olanzapine or Conventional Antipsychotics

Journal of geriatric psychiatry and neurology, 2015-03, Vol.28 (1), p.67-79

2015

Volltextzugriff (PDF)

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia

Journal of clinical psychopharmacology, 2008-12, Vol.28 (6), p.601-607

2008

Volltextzugriff (PDF)

Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods

Schizophrenia research, 2009-08, Vol.113 (1), p.34-40

2009

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(53)
Dissertationen
(1)

Sprache

Englisch
(54)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Psychiatry
(34)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(27)
Male
(26)
Female
(25)
Antipsychotic Agents - Therapeutic Use
(22)
Schizophrenia
(20)
Schizophrenia - Drug Therapy
(20)
Adult
(18)
Treatment Outcome
(18)
Benzodiazepines - Therapeutic Use
(13)
Psychiatric Status Rating Scales
(13)
Schizophrenic Psychology
(13)
Biological And Medical Sciences
(12)
Double-Blind Method
(12)
Olanzapine
(11)
Psychology. Psychoanalysis. Psychiatry
(11)
Aged
(10)
Medical Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE

The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

Mating-Induced c-fos Expression Patterns Complement and Supplement Observations after Lesions in the Male Syrian Hamster Brain

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

Expression of c-fos gene activation during rough and tumble play in juvenile rats

Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

Mating‐Induced c‐fos Expression Patterns Complement and Supplement Observations after Lesions in the Male Syrian Hamster Braina

Incidence of Tardive Dyskinesia in Older Adult Patients Treated With Olanzapine or Conventional Antipsychotics

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia

Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods

Suchergebnisse filtern